logo
4 Ways To Build Your Personal Brand On LinkedIn

4 Ways To Build Your Personal Brand On LinkedIn

Forbes9 hours ago

entrepreneur working on building her brand on LinkedIn
LinkedIn isn't just for job hunting anymore. With over 1.2 billion members worldwide, the platform has become essential for entrepreneurs, students, and professionals building their careers. But most people use it wrong.
They treat LinkedIn like a digital resume instead of a relationship-building tool. They lurk instead of engaging. They connect without purpose. The result? A forgettable presence that generates zero opportunities.
Building a strong personal brand on LinkedIn doesn't require thousands of followers or executive credentials. It requires intention, consistency, and clarity about what you want to be known for. Whether you're a teen entrepreneur launching your first venture or an executive pivoting careers, these four strategies will help you stand out and attract the right opportunities.
Your LinkedIn profile is your digital handshake. In some cases it's the first time someone is 'meeting you'. You want to make it count. You want to make a great impression.
Start with your headline—the 120 characters that appear under your name everywhere on LinkedIn. Most people waste this prime real estate with generic titles like "Student at University" or 'Aspiring Marketing Professional' or 'Looking to connect'. Instead, use it to communicate value and give people a reason to keep reading.
Compare these examples:
Your headline should immediately tell visitors what you do and who you serve. This approach attracts the right connections and repels the wrong ones.
The "About" section functions as your elevator pitch in written form. Keep it conversational and human. Share your "why" and include specific accomplishments that demonstrate your expertise. Think of it less like a resume summary and more like the bio you'd want to read if you were being introduced at a conference.
Don't overlook the banner image—customize it with your website URL, tagline, or visual elements that reinforce your professional identity. This small detail signals that you take your online presence seriously.
LinkedIn rewards creators who publish original content consistently. Most users consume content passively, creating an opportunity for those willing to share their perspectives.
Choose two to three content pillars—topics you want to be known for—and rotate through them in your posts. For a young entrepreneur, these might include:
For professionals in traditional careers, content pillars might focus on industry trends, career development insights, or lessons from specific projects.
The key is consistency over perfection. Publishing one thoughtful post per week beats sporadic bursts of activity. If writing full posts feels overwhelming, start by commenting meaningfully on others' content. Add genuine insights, ask thoughtful questions, and tag relevant connections when appropriate.
LinkedIn's algorithm currently favors diverse content formats. Experiment with polls to gather audience insights, carousel posts to share step-by-step processes, and short videos to add personality to your brand.
Focus on content that provides genuine value to your network. Share specific lessons from recent projects, industry observations with your unique perspective, or resources that have helped your professional growth. Avoid overly promotional posts—LinkedIn users respond better to authentic insights than sales pitches. When sharing wins, include the challenges you faced and lessons learned, plus credit the team members, mentors, or collaborators who helped make success possible. This approach builds credibility while positioning you as someone worth following and connecting with.
Most people overlook the Featured section on their LinkedIn profile—but if you're trying to stand out, this is prime real estate. It's where you can pin work you're proud of and make it easy for someone skimming your profile to get a clear sense of what you do.
Think beyond a generic link. Use this space to showcase:
Make it easy for people to understand your value, without scrolling too far. For job seekers, it could showcase presentations, published articles, or volunteer work that demonstrates relevant skills.
This section transforms casual profile visitors into engaged prospects. When someone clicks through to your Featured content, they're actively choosing to learn more about your work—a strong signal of genuine interest.
LinkedIn connections without context create hollow networks. The goal isn't to accumulate connections but to build meaningful professional relationships.
When sending connection requests, always include a personalized note. Generic invitations get ignored or rejected. Personalized messages start conversations.
Effective connection messages follow this structure:
Example: "I appreciated your recent post about sustainable business practices—especially your point about balancing profit with purpose. As someone building an eco-friendly product line, I'd love to connect and learn from your experience."
After connecting, don't disappear. Engage with their content thoughtfully, offer assistance when relevant, and share valuable resources. These interactions foster genuine relationships that generate opportunities over time.
Quality matters more than quantity. A network of 500 engaged connections who know your work generates more value than 5,000 strangers who barely remember connecting with you.
Personal branding on LinkedIn isn't about creating a false persona or chasing viral content. It comes down to showing up consistently—and making it clear what you're all about. The people who really thrive on LinkedIn aren't just posting for attention. They're adding value. They share what they're learning, highlight others' wins, and take part in real conversations within their industry. Over time, that kind of presence builds trust and makes people want to stay connected.
Start with one element: update your headline, publish your first post, or send five personalized connection requests. Small, consistent actions compound over time to create a powerful professional presence.
Your brand is already forming in every LinkedIn interaction, post, and connection. The question is whether you're shaping it intentionally or letting it develop by default.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How the Federal Reserve Fuels Fiscal Profligacy
How the Federal Reserve Fuels Fiscal Profligacy

Wall Street Journal

time33 minutes ago

  • Wall Street Journal

How the Federal Reserve Fuels Fiscal Profligacy

If Republicans are serious about reducing federal deficit spending, it is important to consider the effect the Federal Reserve has on the nation's budgetary outlook. If the numerical models imposed by the Congressional Budget Office drive fiscal policy, lawmakers also need to understand what they portend for monetary policy. The Fed once was committed to 'normalizing' its balance sheet—shrinking its footprint in credit markets by reducing the size of its portfolio of Treasury debt and mortgage-backed securities. Chairman Jerome Powell noted in a 2019 speech that large-scale asset purchases by the Fed over the previous 10 years had been viewed from the outset as 'extraordinary measures to be unwound, or 'normalized,' when conditions ultimately warranted.'

Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice

Yahoo

time42 minutes ago

  • Yahoo

Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice

Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Rare earth supply risks: Is Tesla the real target by China?
Rare earth supply risks: Is Tesla the real target by China?

Yahoo

time43 minutes ago

  • Yahoo

Rare earth supply risks: Is Tesla the real target by China?

-- With China granting rare earth export licenses to GM, Ford, and Stellantis (NYSE:STLA) but not to Tesla (NASDAQ:TSLA), questions are mounting over whether Tesla is being deliberately targeted amid ongoing trade tensions and Musk's outspoken foreign policy stance. 'Media reports only indicate GM, F & STLA received licenses. This implies TSLA & RIVN could still be waiting for licenses. It's possible this is the consequence of Musk's aggressive stance on foreign policy & China's aim to support local EV makers,' Wells Fargo wrote, citing expert Dr. Gracelin Baskaran. China controls nearly 100% of global supply for the seven most critical heavy rare earth elements, or REEs, which are essential for electric vehicle motors and other advanced manufacturing. The U.S. auto sector is the largest end-user of these materials, but America's consumption is a fraction of global output—just 6,600 tonnes out of 390,000 tonnes produced last year. Following China's April 4 restrictions, automakers had only 2-3 months of buffer stock, and those reserves are now running low. While the six-month licenses keep operations running for some U.S. automakers, Wells Fargo warns the current arrangement is 'still a band-aid, not a fix,' with supply risks likely to persist for another two to five years as new capacity ramps up outside China. For now, China's selectivity in granting licenses and vigilance over end-use means Tesla—and other OEMs still waiting—could face mounting pressure until global rare earth supply chains diversify. Related articles Rare earth supply risks: Is Tesla the real target by China? 2025 Global Technology Conference: What did we learn? Has AI started replacing junior software developers? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store